Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 30, 2020 13:35:52 GMT -5
Just playing the devil here, but would there be a reason for Gilead to use technosphere instead of aerosol or pump type inhaler like is often used for asthma ? I believe so. Cayston® aztreonam for inhalation solution 75 mg/vial AmBisome® amphotericin b liposome for injection 50 mg/vial and their MAB's. www.gilead.com/science-and-medicine/pipelineIt will depend on the dosage amount. Let's hope GILD will choose TS and the cartridge will hold enough of REM to be effective.
|
|
|
Post by radgray68 on Apr 30, 2020 13:44:02 GMT -5
Hope it's as easy as saying to Big Pharma: Do you want to get 30% of the drug into the lungs? Or, would you like to get 70% deep into the lungs?
|
|
|
Post by mango on Apr 30, 2020 13:44:28 GMT -5
MannKind's DPI platform is superior to the outdated DPIs on the market and also outperform aerosol therapy as well. In addition, MannKind's inhalers are cheap to make. Furthermore, less treatment burden, drawbacks and limitations are associated with MannKind's DPI platform compared with aerosol therapy and DPIs and MDIs on the market today. I have covered the comparisons in past posts if you search for it you will find them where I went into great detail (I don't have time at the moment to search for them). 🤘 . Is not their Remdesivir meant for those on ventilators only? If so, would they even be capable of inhaling well? Remdesivir is only for vent patients? No. Gilead Trials• Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19. •The first of two studies will evaluate the safety and efficacy of both a 5-day and a 10-day dosing duration of remdesivir, in addition to standard of care, for patients with severe manifestations of COVID-19. The second study will evaluate the safety and efficacy of the same dosing regimens of remdesivir in addition to standard of care for patients with moderate manifestations of COVID-19, compared with standard of care alone. Other Trials• Health authorities in China have initiated two clinical trials in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus. The two studies are being coordinated by the China-Japan Friendship Hospital and are being conducted at multiple sites in Hubei province. Gilead is providing study drug at no charge and provided input on study design and conduct. • One study is evaluating remdesivir in patients with confirmed disease who have developed more severe clinical manifestations such as a requirement for supplemental oxygen. The other study is evaluating remdesivir in patients with confirmed COVID-19 infection who have been hospitalized but are not displaying significant clinical manifestations of disease such as an oxygen requirement. • The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated a Phase 2 adaptive, randomized, double-blind, placebo-controlled trial into remdesivir as a potential treatment for hospitalized adult patients diagnosed with COVID-19. Gilead is providing study drug at no charge and provided input on study design and conduct. Additionally, INSERM in France has initiated a study evaluating remdesivir and other potential treatments, using a master protocol developed by WHO. Gilead is providing study drug at no charge and provided input on study design and conduct. www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trialsLastly,
|
|
|
Post by peppy on Apr 30, 2020 14:07:07 GMT -5
. Is not their Remdesivir meant for those on ventilators only? If so, would they even be capable of inhaling well? Remdesivir is only for vent patients? No. Gilead Trials• Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19. •The first of two studies will evaluate the safety and efficacy of both a 5-day and a 10-day dosing duration of remdesivir, in addition to standard of care, for patients with severe manifestations of COVID-19. The second study will evaluate the safety and efficacy of the same dosing regimens of remdesivir in addition to standard of care for patients with moderate manifestations of COVID-19, compared with standard of care alone. Other Trials• Health authorities in China have initiated two clinical trials in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus. The two studies are being coordinated by the China-Japan Friendship Hospital and are being conducted at multiple sites in Hubei province. Gilead is providing study drug at no charge and provided input on study design and conduct. • One study is evaluating remdesivir in patients with confirmed disease who have developed more severe clinical manifestations such as a requirement for supplemental oxygen. The other study is evaluating remdesivir in patients with confirmed COVID-19 infection who have been hospitalized but are not displaying significant clinical manifestations of disease such as an oxygen requirement. • The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated a Phase 2 adaptive, randomized, double-blind, placebo-controlled trial into remdesivir as a potential treatment for hospitalized adult patients diagnosed with COVID-19. Gilead is providing study drug at no charge and provided input on study design and conduct. Additionally, INSERM in France has initiated a study evaluating remdesivir and other potential treatments, using a master protocol developed by WHO. Gilead is providing study drug at no charge and provided input on study design and conduct. www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trialsLastly, Mango and all, did you email mike?
|
|
|
Post by ppallap on Apr 30, 2020 14:14:47 GMT -5
|
|
|
Post by mango on Apr 30, 2020 14:32:37 GMT -5
Remdesivir is only for vent patients? No. Gilead Trials• Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19. •The first of two studies will evaluate the safety and efficacy of both a 5-day and a 10-day dosing duration of remdesivir, in addition to standard of care, for patients with severe manifestations of COVID-19. The second study will evaluate the safety and efficacy of the same dosing regimens of remdesivir in addition to standard of care for patients with moderate manifestations of COVID-19, compared with standard of care alone. Other Trials• Health authorities in China have initiated two clinical trials in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus. The two studies are being coordinated by the China-Japan Friendship Hospital and are being conducted at multiple sites in Hubei province. Gilead is providing study drug at no charge and provided input on study design and conduct. • One study is evaluating remdesivir in patients with confirmed disease who have developed more severe clinical manifestations such as a requirement for supplemental oxygen. The other study is evaluating remdesivir in patients with confirmed COVID-19 infection who have been hospitalized but are not displaying significant clinical manifestations of disease such as an oxygen requirement. • The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated a Phase 2 adaptive, randomized, double-blind, placebo-controlled trial into remdesivir as a potential treatment for hospitalized adult patients diagnosed with COVID-19. Gilead is providing study drug at no charge and provided input on study design and conduct. Additionally, INSERM in France has initiated a study evaluating remdesivir and other potential treatments, using a master protocol developed by WHO. Gilead is providing study drug at no charge and provided input on study design and conduct. www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trialsLastly, Mango and all, did you email mike? Some folks on ST said they emailed Mike, but the more the better I would think. 🤞🤞🤞🤞🤞
|
|
|
Post by mango on Apr 30, 2020 15:11:13 GMT -5
|
|
|
Post by falconquest on Apr 30, 2020 15:31:07 GMT -5
Before everyone gets all googly eyed, do we even know (or can we know) if Remdesivir is able to be loaded onto the Technosphere particle?
|
|
|
Post by goyocafe on Apr 30, 2020 16:04:37 GMT -5
Before everyone gets all googly eyed, do we even know (or can we know) if Remdesivir is able to be loaded onto the Technosphere particle? We don't know. I suspect our trepidation is based on history. We can only HOPE MNKD is all over these opportunities and at least doing the leg work to find out.
|
|
|
Post by mango on Apr 30, 2020 16:23:06 GMT -5
Before everyone gets all googly eyed, do we even know (or can we know) if Remdesivir is able to be loaded onto the Technosphere particle? I would venture to guess it is plausible. Remdesivir is an adenosine analog, correct? Organic compound. Seems like there is very little that can't be loaded onto Technosphere. 🤞
|
|
|
Post by sellhighdrinklow on Apr 30, 2020 16:31:33 GMT -5
Maybe this is why Sports' boss bought 20,000 shares recently.
|
|
|
Post by peppy on Apr 30, 2020 16:56:54 GMT -5
Before everyone gets all googly eyed, do we even know (or can we know) if Remdesivir is able to be loaded onto the Technosphere particle? I would venture to guess it is plausible. Remdesivir is an adenosine analog, correct? Organic compound. Seems like there is very little that can't be loaded onto Technosphere. 🤞 There is no package insert for Remdesivir. That said, another VIR. vir; -vir / antiviral; anti-HIV Looking then at tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate. VIREAD® (tenofovir disoproxil fumarate) 11 DESCRIPTION VIREAD is the brand name for tenofovir disoproxil fumarate (a prodrug of tenofovir) which is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5’-monophosphate. Tenofovir exhibits activity against HIV-1 reverse transcriptase. The chemical name of tenofovir disoproxil fumarate is 9-[(R)-2 [[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C19H30N5O10P • C4H4O4 and a molecular weight of 635.52. It has the following structural formula:
|
|
|
Post by sportsrancho on Apr 30, 2020 19:43:59 GMT -5
Maybe this is why Sports' boss bought 20,000 shares recently. This is all very interesting but I can guarantee you this is not why Bill bought 20,000 shares.
|
|
|
Post by sportsrancho on Apr 30, 2020 19:45:07 GMT -5
That would be a BAD question because he does not know the answer. If Mike answered NO....it could hurt the stock price. And Mike wont say yes because they are still working out the details of a possible collaboration. I think it would be a great question. MNKD just has to reply with “We can’t comment on that”. Very smart.. love it
|
|
|
Post by itellthefuture777 on May 1, 2020 12:31:56 GMT -5
|
|